Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01275612
Other study ID # CIS/MSC 08
Secondary ID 2008-007485-35
Status Withdrawn
Phase Phase 1
First received January 11, 2011
Last updated March 20, 2018
Start date November 2010
Est. completion date March 19, 2018

Study information

Verified date March 2018
Source Mario Negri Institute for Pharmacological Research
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot, explorative, study to test the feasibility and safety of systemic infusion of donor ex-vivo expanded Mesenchymal Stem Cells to repair the kidney and improve function in patients with solid organ cancers who develop acute renal failure after chemotherapy with cisplatin.


Description:

Since its introduction into clinical trials, cisplatin (cis-diammine-dichloro-platinum) has had a major impact in cancer medicine, changing the course of therapeutic management of several tumors, such as those of ovary, testes, and the head and neck. Unfortunately, in addition to causing bone marrow suppression, ototoxicity, and anaphylaxis, dose-dependent and cumulative nephrotoxicity is the major toxicity of this compound, sometimes requiring a reduction in dose or discontinuation of treatment. Approximately 25-35% of patients develop evidence of nephrotoxicity following an initial dose (50-100 mg/m2) of cisplatin, due to its preferential accumulation within the proximal tubular cells in the outer medulla of the kidney. Tubular cell events activated by cisplatin toxicity translate into the fact that cisplatin predictably lowers glomerular filtration rate (GFR) in a clear dose-dependent manner even after a single drug exposure. Early proteinuria is mild, as it is glycosuria. Overall these findings indicate that there is a pressing need for way to protect the kidney while administering effective chemotherapeutic agents such as cisplatin.

Present strategies for the treatment of acute renal failure have focused on targeting individual mechanisms thought to contribute to ischemic or toxic insults to the kidney.An alternative possibility is to adopt a novel strategy that would allow regeneration of the injured renal tissue. Renal recovery following acute tubular injury, like that induced by cisplatin treatment, is often a slow process requiring many days to weeks to occur. Attempts to accelerate recovery have focused on the administration of growth factors, hepatocyte growth factor, or insulin-like growth factor-1. While growth factor therapy has been successful in experimental models, no beneficial effects have been observed in limited clinical trials. The ability of extrarenal cells to participate in the regenerative response following post-transplant acute renal failure may hold true for acute renal failure that develops in native kidneys after cisplatin therapy. The rationale for this approach rests on the recent demonstration in mice and in athymic nude rats that stem cells from bone marrow can be used to grow new muscle or blood vessels in heart tissue that has been damaged after myocardial infarction. Similarly, consistent evidence of the beneficial effect of bone-marrow derived cell therapy has been recently reported in humans with ischemic heart disease. This approach has been also successfully extended to repair ischemically and cisplatin injured renal tubules in mice. The observation raises the possibility that adult-derived bone marrow cells could be administered to enhance the recovery from renal injury. Although no human data so far are available, we expect that ex-vivo expanded donor bone-marrow derived mesenchymal stromal cells (MSC) infusion would allow to accelerate tubular regeneration and thus renal function recovery in patients with cisplatin-induced acute renal failure, a disease that, like ischemically-induced acute renal injury, so far has no cure.

Up to now there is no clinical study of repair tissue injury in patients with acute renal failure due to ischemic or toxic insults. Nevertheless, there are clinical data on the effectiveness of MSC infusion in other diseases/conditions like as inborn errors of metabolism,osteogenesis imperfecta,allogeneic HSC transplantation, treatment of acute GVHD, acute myocardial infarction.

The aim of this pilot, explorative, study is to test the feasibility and safety of systemic infusion of donor ex-vivo expanded MSC to repair the kidney and improve function in patients with solid organ cancers who develop acute renal failure after chemotherapy with cisplatin.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 19, 2018
Est. primary completion date March 19, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Male and female patients

- Requiring cisplatin therapy (>80mg/m2) against advanced head and neck carcinoma, non-small cell lung cancer stage IIIB/IV, bladder transitional cell carcinoma locally advanced or metastatic, which are not amenable to surgical resection or ablation with curative intent

- An Eastern Cooperative Oncology Group performance status (ECOG PS) <2

- Normal renal, hepatic and bone marrow function

- Physician's assessment of life expectancy: 4-10 months

- Aged > 18 years

- Evidence of acute renal injury as assessed by percent increase of NGAL concentration in spot urine > 3500% over baseline values at day 2 post-cisplatin infusion

- Written informed consent

Exclusion Criteria:

- Specific contraindication to MSC infusion

- Serious concomitant diseases not adequately responding to specific therapy

- Symptomatic brain metastases

- Pregnancy

- Previous cisplatin infusion

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Mesenchymal stromal cell infusion
The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.

Locations

Country Name City State
Italy Unit of Oncology - Ospedali Riuniti of Bergamo Bergamo BG

Sponsors (1)

Lead Sponsor Collaborator
Mario Negri Institute for Pharmacological Research

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum creatinine concentration. To evaluate the rate of renal function loss up to 15 days post-cisplatin infusion. 15 days post-cisplatin infusion
Secondary Neutrophil gelatinase-associated lipocalin (NGAL) At days 0,2,5,7,12,15,18 and 30.
Secondary N-acetyl-p- D glucosaminidase enzyme (NAG) At days 0,2,5,7,12,15,18 and 30.
See also
  Status Clinical Trial Phase
Recruiting NCT05538351 - A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03938038 - Guidance of Ultrasound in Intensive Care to Direct Euvolemia N/A
Recruiting NCT05805709 - A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial N/A
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT05897840 - Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients N/A
Recruiting NCT04986137 - Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT04095143 - Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
Not yet recruiting NCT06026592 - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Not yet recruiting NCT06064305 - Transcriptional and Proteomic Analysis of Acute Kidney Injury
Terminated NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Terminated NCT03305549 - Recovery After Dialysis-Requiring Acute Kidney Injury N/A
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Terminated NCT02860130 - Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Phase 3
Completed NCT06000098 - Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
Not yet recruiting NCT05548725 - Relation Between Acute Kidney Injury and Mineral Bone Disease
Completed NCT02665377 - Prevention of Akute Kidney Injury, Hearttransplant, ANP Phase 3
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A